Novartis AG (NVS)
| Market Cap | 294.91B +15.9% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.48 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 23.33 |
| Forward PE | 16.64 |
| Dividend | $3.08 (2.04%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 4,358,807 |
| Open | 156.08 |
| Previous Close | 156.27 |
| Day's Range | 149.17 - 156.08 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 154.65 (+2.34%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $154.65, which is an increase of 2.34% from the latest price.
News
Novartis AG Remibrutinib in MS Investor Call Transcript
Novartis AG Remibrutinib in MS Investor Call Transcript
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activit...
Novartis AG Transcript: Investor update
REMODEL-1 and -2 showed lower relapse and MRI activity, with a significant 6-month disability-progression benefit and a favorable reported safety profile. Management sees $4bn-plus RMS potential, with further SPMS upside and broader pipeline opportunities.
Novartis AG Slides: Investor update
Novartis AG has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Novartis (NVS) Reports Positive Phase 3 Trial Results for Multiple Sclerosis Treatment Remibrutinib
Novartis (NVS) Reports Positive Phase 3 Trial Results for Multiple Sclerosis Treatment Remibrutinib
Novartis says remibrutinib showed comprehensive disease control in Phase 3 trial
Novartis (NVS) presented positive results from the pivotal Phase 3 REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, showing that remibrutinib, a highly selective and efficacious oral Br...
Novartis' Kisqali reduces risk of death by 19.1% in 6-year breast cancer study
Novartis reported positive 6-year trial results for its breast cancer drug, Kisqali, showing improved survival rates of 19.1% and lasting benefits from treatment.
Novartis's Kisqali Shows Six-Year Survival Benefit In Early Breast Cancer
(RTTNews) - Novartis (NVS) reported new six-year results from the Phase 3 NATALEE trial showing that Kisqali (ribociclib) plus endocrine therapy (ET) improved overall survival compared with endocrine ...
Novartis announces results from six-year follow up study of Kisqali
Novartis (NVS) announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival data with Kisqali plus endocrine therap...
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica
Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica
Novartis announces European Commission approval for Cosentyx in PMR
Novartis (NVS) announced that the European Commission has approved Cosentyx for the treatment of adults with polymyalgia rheumatica, or PMR, who have had an inadequate response to glucocorticoids or w...
Novartis (NVS) Gains FDA Orphan Designation for Rapcabtagene Autoleucel in Rare Muscle Disorders
Novartis (NVS) Gains FDA Orphan Designation for Rapcabtagene Autoleucel in Rare Muscle Disorders
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
Novartis (NVS)’ rapcabtagene autoleucel received FDA orphan designation for treatment of idiopathic inflammatory myopathies, according to a post to the agency’s website.
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
Novartis (NVS)’ rapcabtagene autoleucel received FDA orphan designation for treatment of idiopathic inflammatory myopathies gets orphan designation, according to a post to the agency’s website.
Women see five or six doctors to figure out menopause symptoms. A top Novartis exec says AI could finally connect the dots
At Fortune’s MPW Summit, top health care leaders said midlife care is too fragmented, and AI could help women put the pieces together.
Novartis terminates mid-stage trial of lupus nephritis treatment, Endpoints says
Novartis (NVS) has scrapped a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” Endpoints News’ Lei Lei Wu reports, citing a federal clinical trials database. Publishe...
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical tr...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contac...
Novartis (NVS) Gains FDA Approval for Lamprene, Enhancing Patient Access
Novartis (NVS) Gains FDA Approval for Lamprene, Enhancing Patient Access
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...